Edition:
United States

MediciNova Inc (MNOV.A)

MNOV.A on American Stock Exchange

7.49USD
17 Jan 2018
Change (% chg)

$-0.26 (-3.35%)
Prev Close
$7.75
Open
--
Day's High
$7.49
Day's Low
$7.49
Volume
0
Avg. Vol
219
52-wk High
$7.75
52-wk Low
$4.41

Latest Key Developments (Source: Significant Developments)

MediciNova completes off-floor distribution
Monday, 16 May 2016 09:20pm EDT 

MediciNova Inc : Says it completes the off-floor distribution of shares on May 17 .Says 800,000 shares of its common stock were sold at the price of 644 yen per share.  Full Article

MediciNova to offer off-floor distribution of 800,000 shares
Monday, 16 May 2016 03:20am EDT 

MediciNova Inc <4875.T>: Says it to offer an off-floor distribution of 800,000 shares of its stock at the price of 644 yen per share, on the Tokyo Stock Exchange on May 17 .Says the limitation for purchase of the distribution is up to 10,000 shares for each customer.  Full Article

MediciNova to offer off-floor distribution of shares
Tuesday, 10 May 2016 02:43am EDT 

MediciNova Inc : Says it to offer an off-floor distribution of 800,000 shares on Tokyo Stock Exchange between May 17 and May 19 . Says offering price will be determined based on the closing share price of the day before the distribution .Says the limitation for distribution is up to 1,000 shares for each customer.  Full Article

MediciNova Inc announces interim data from clinical trial of MN-166 (ibudilast) in ALS
Wednesday, 20 Apr 2016 06:00am EDT 

MediciNova Inc:Announces interim data from clinical trial of MN-166 in ALS presented at the American Academy of Neurology 68th annual meeting in Vancouver, Canada.No cluster of adverse events was differentially present in MN-166 treatment and placebo treatment subjects.  Full Article

MediciNova Inc announces Ryan Selhorn as new CFO
Thursday, 31 Mar 2016 06:30am EDT 

MediciNova Inc:Appoints Ryan Selhorn as new CFO effective March 31.  Full Article

MediciNova Inc receives notice of allowance for new patent covering MN-001 in China
Sunday, 27 Mar 2016 07:00pm EDT 

MediciNova Inc:Says it has received a notice of allowance from the Chinese Patent Office for a new patent which covers MN-001 (tipelukast).Says the allowed claims cover the compound as a polymorphic form of MN-001 (tipelukast), pharmaceutical compositions, and manufacturing processes.Says the allowed claims cover oral administration including tablets and capsule.  Full Article

MediciNova Inc Receives Notice of Allowance for New Patent Covering MN-001 and MN-002
Wednesday, 23 Mar 2016 07:00pm EDT 

MediciNova Inc:Says it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application which covers MN-001 (tipelukast) and MN-002 (a major metabolite of MN-001) for the treatment of hypertriglyceridemia, hypercholesterolemia, and hyperlipoproteinemia.  Full Article

MediciNova Inc receives fast track designated approval from FDA for MN-166
Tuesday, 22 Mar 2016 06:00am EDT 

MediciNova Inc:Receives FDA fast track designated approval for MN-166 for the treatment of progressive multiple sclerosis.  Full Article

MediciNova Inc receives patent for MN-166 in U.S.
Monday, 7 Mar 2016 06:00pm EST 

MediciNova Inc:Receives a patent for MN-166 (for amyotrophic lateral sclerosis (ALS) treatment) in U.S., with valid as of July 2028.  Full Article

MediciNova Inc announces positive result of phase II clinical trials of MN-166
Sunday, 6 Mar 2016 06:00pm EST 

MediciNova Inc:Announces positive result of the phase II clinical trial for MN-166 (for Opioid Use Disorder treatment) in the United States on March 5.  Full Article

BRIEF-Medicinova Announces Positive Top-Line Results From Clinical Trial Of MN-166 (ibudilast) In ALS

* MEDICINOVA ANNOUNCES POSITIVE TOP-LINE RESULTS FROM THE CLINICAL TRIAL OF MN-166 (IBUDILAST) IN ALS